96. Crohn disease
2,209 clinical trials,   1,276 drugs   (DrugBank: 240 drugs),   166 drug target genes,   210 drug target pathways

Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-002319-26-HU
(EUCTR)
24/11/200623/03/2006Efficacy and safety of AZD9056 200 mg once daily versus placebo in adult patients with active Crohn’s disease – A randomized, double-blind, pilot, four week, parallel-group, multicentre, phase II studyEfficacy and safety of AZD9056 200 mg once daily versus placebo in adult patients with active Crohn’s disease – A randomized, double-blind, pilot, four week, parallel-group, multicentre, phase II study Crohn's diseaseProduct Code: AZD9056AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
40Phase 2Hungary;Germany;Belgium;Austria
2EUCTR2005-002319-26-AT
(EUCTR)
05/04/200622/02/2006Efficacy and safety of AZD9056 200 mg once daily versus placebo in adult patients with active Crohn’s disease – A randomized, double-blind, four week, parallel-group, multicentre, phase II study - POPCRONEfficacy and safety of AZD9056 200 mg once daily versus placebo in adult patients with active Crohn’s disease – A randomized, double-blind, four week, parallel-group, multicentre, phase II study - POPCRON Crohn's diseaseProduct Code: AZD9056AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
40Phase 2Hungary;Germany;Belgium;Austria
3EUCTR2005-002319-26-BE
(EUCTR)
23/12/200513/12/2005Efficacy and safety of AZD9056 200 mg once daily versus placebo in adult patients with active Crohn’s disease – A randomized, double-blind, four week, parallel-group, multicentre, phase II studyEfficacy and safety of AZD9056 200 mg once daily versus placebo in adult patients with active Crohn’s disease – A randomized, double-blind, four week, parallel-group, multicentre, phase II study Crohn's diseaseProduct Code: AZD9056AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
40Phase 2Hungary;Germany;Belgium;Austria
4EUCTR2005-002319-26-DE
(EUCTR)
20/12/200528/10/2005Efficacy and safety of AZD9056 200 mg once daily versus placebo in adult patients with active Crohn’s disease – A randomized, double-blind, four week, parallel-group, multicentre, phase II studyEfficacy and safety of AZD9056 200 mg once daily versus placebo in adult patients with active Crohn’s disease – A randomized, double-blind, four week, parallel-group, multicentre, phase II study Crohn's diseaseProduct Code: AZD9056AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
40Phase 2Hungary;Germany;Belgium;Austria